Tag Archives: patient advocacy

Harder, Better, Faster, Stronger: Takeaways from Partnering For Cures 2012

Drug Manufacturing

The chorus to Kanye West’s 2007 chart-topper Stronger can teach us volumes about speeding drug development. Harder:  Drug development is challenging.  It takes over 10 years and more than $1 billon to bring a therapy through the product pipeline, from the research lab to clinical trials to FDA approval to prescription to patients suffering from the disease. The FDA approved over 30 innovative drugs last year, including more than 10 new treatments for cancer—a good Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

FDASIA: A Step Forward for Patients

fdasia-panel

Earlier this year, Congress passed and President Obama signed the FDA Safety and Innovation Act (FDASIA) which included a re-authorization of the Prescription Drug User Fee Act (PDUFA). PDUFA provides essential funding to the FDA by authorizing the agency to charge user fees to companies seeking to have products reviewed. Originally enacted in 1992, it must be reauthorized every 5 years. Sara Radcliffe, executive vice president of health at BIO, moderated a panel of experts and advocates Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,

eAdvocacy Summit Brings Together More Than 130 Groups

eAdvocacy-Summit-btn

BIO’s mission is to champion biotechnology issues by advocating for policies that will enable the realization of breakthrough products to cure disease, feed the hungry, and clean our environment. Fortunately, we are not alone – our many alliance and advocacy partners share our goal. When smart, like-minded people get together, good things tend to happen. That’s why I’m looking forward to tomorrow’s eAdvocacy Summit here in Washington, DC. The Global Healthy Living Foundation (GHLF) and Read More >

Events  |  Leave a comment  |  Email This Post
Tags: ,

BIO Technology Transfer Symposium: Funding that First $2 Million

2-mill

With creative funding schemes picking up steam and nontraditional funders taking an interest in biotech, what can universities and start-ups expect in their right first-round financing structure? At the BIO Technology Transfer Symposium, a panel examined various funding sources as well as the factors that influence investment decisions and the ins and outs of early stage financing deals. William Tucker, executive director, Innovation Alliances and Services, University of California Office of the President, moderated a Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,